Consensus CONMED Corporation

Stocks

CNMD

US2074101013

Medical Equipment, Supplies & Distribution

Market Closed - NYSE Other stock markets 00:00:02 28/07/2026 +04			5-day change	1st Jan Change
43.51 ^USD	+1.94%		+0.14%	+7.17%

07-22	Conmed Says AirSeal Cleared for Use With Intuitive da Vinci 5 Hex Cannula	MT
07-14	Conmed Shares Rise After Company Mulls Sale Amid Takeover Interest	MT

Evolution of the Average Target: CONMED Corporation

Evolution of the Target Price: CONMED Corporation

Changes in Analyst Recommendations: CONMED Corporation

7cad7b390ae3a3898bfc44e72b1a.-y3JWyY4vlm_ZM_WUPggq2n_NGxBiw4u8NqDfCdSNzg.qFmLAm0P_Q37I_6_NKda4STGcygp0VtenZDbK0thQl6DWpY9HmfHadMplg~872548549853e04fca6c6a6a8cb281e7

Analysts' recommendations: CONMED Corporation

07-09	BMO Capital Initiates CONMED at Market Perform With $36 Price Target	MT
06-29	CONMED Lagging Medtech Peers as Growth Slows, BofA Securities Says	MT
06-29	BofA Downgrades CONMED to Underperform From Neutral, Keeps $40 Price Target	MT
05-18	BofA Securities Adjusts CONMED Price Target to $40 From $52	MT
03-17	Piper Sandler Downgrades CONMED to Neutral From Overweight, Adjusts PT to $39 From $55	MT
12/06/25	Conmed Shares Fall After Needham Downgrade	MT
12/06/25	Needham Downgrades CONMED to Hold From Buy, Removes $61 Price Target	MT
28/04/25	Stifel Downgrades CONMED to Hold From Buy, Adjusts Price Target to $55 From $75	MT
06/02/25	JPMorgan Downgrades CONMED to Neutral From Overweight, Adjusts Price Target to $70 From $85	MT
01/08/24	Needham Adjusts CONMED's Price Target to $97 From $106, Keeps Buy Rating	MT
25/07/24	Needham Trims Price Target on CONMED to $106 From $107, Keeps Buy Rating	MT
25/04/24	Wells Fargo Adjusts Price Target on CONMED to $77 From $98, Maintains Equalweight Rating	MT
25/04/24	Needham Lowers Price Target on CONMED to $107 From $129, Notes Slight Guidance Cut Due to Currency, Keeps Buy Rating	MT
01/02/24	Needham Adjusts Price Target on CONMED to $129 From $119, Maintains Buy Rating	MT
01/02/24	JPMorgan Cuts CONMED Price Target to $115 From $135, Maintains Overweight Rating	MT
27/10/23	Piper Sandler Adjusts Price Target on CONMED to $130 From $145, Maintains Overweight Rating	MT
26/10/23	Wells Fargo Cuts Price Target on CONMED to $107 From $123, Maintains Equalweight Rating	MT
27/07/23	Needham Adjusts Price Target on CONMED to $140 From $139, Maintains Buy Rating	MT
27/07/23	Keybanc Adjusts Price Target on CONMED to $141 From $131, Maintains Overweight Rating	MT
05/06/23	Needham Raises Price Target on CONMED to $139 From $135, Keeps Buy Rating	MT
22/05/23	CL King Starts CONMED at Buy With $140 Price Target	MT
27/04/23	Piper Sandler Raises CONMED's Price Target to $128 From $118, Maintains Overweight Rating	MT
27/04/23	Wells Fargo Adjusts Price Target on CONMED to $119 From $96, Maintains Equal-Weight Rating	MT
27/04/23	Needham Adjusts Price Target on CONMED to $135 From $122, Reiterates Buy Rating	MT
27/04/23	Keybanc Adjusts Price Target on CONMED to $131 From $124, Maintains Overweight Rating	MT

More recommendations

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Objective/dr gap
CONMED CORPORATION	-	-8.62%
ABBOTT LABORATORIES		+15.59%
MEDTRONIC PLC		+17.58%
CENCORA, INC.		+14.83%
HOYA CORPORATION		+23.7%
BECTON, DICKINSON AND COMPANY		+14.71%
MEDLINE INC.		+31.41%
DEXCOM, INC.		+20.38%
WEST PHARMACEUTICAL SERVICES, INC.		+22.77%
STERIS PLC		+17.99%
Average		+17.03%
Weighted average by Cap.		+18.10%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

42.68USD

Average target price

39.00USD

Spread / Average Target

-8.62%

High Price Target

40.00USD

Spread / Highest target

-6.28%

Low Price Target

36.00USD

Spread / Lowest Target

-15.65%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

BMO Capital
BofA Securities
Piper Sandler
Needham & Co.
Stifel Nicolaus
JPMorgan Chase
Wells Fargo Securities
KeyBanc Capital Markets
CL King
Jefferies & Co.
UBS
Barclays